23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. - Evidence Based Medicine on FHIR Implementation Guide v2.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Active as of 2024-11-21

Generated Narrative: Citation 179623

version: 7; Last updated: 2024-07-18 17:55:00+0000

Profile: JournalArticleCitation

url: Citation 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

identifier: FEvIR Object Identifier/179623, https://pubmed.ncbi.nlm.nih.gov/23452809, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.39

version: 2.0.0-ballot

title: 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

status: Active

date: 2024-11-21 14:09:14+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

Citation Classification Type fevir-platform-use: FEvIR Platform Use

Medline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2013-04-22

lastReviewDate: 2021-10-21

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source
classifier: MEDLINE

classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate
activity: PubMed Pubstatus of Received
period: ?? --> 2012-11-21

statusDate
activity: PubMed Pubstatus of Revised
period: ?? --> 2012-12-14

statusDate
activity: PubMed Pubstatus of Accepted
period: ?? --> 2012-12-18

statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2013-03-05 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2013-03-05 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2013-04-23 06:00:00+0000

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/23452809, https://doi.org/10.1016/j.urology.2012.12.025, pii/S0090-4295(12)01569-5
Titles
- Type Language Text
* Primary title English
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Abstracts
- Text Copyright
*
OBJECTIVE: To evaluate long-term follow-up of a phase II trial of chemohormonal therapy in 62 men with prostate cancer biochemical relapse (BR). METHODS: Treatment was 4 cycles of docetaxel (70 mg/m(2)) every 3 weeks and estramustine 280 mg three times a day (days 1-5) followed by 15 months of goserelin acetate/bicalutamide. The primary endpoint was the proportion with prostate-specific antigen (PSA) <0.1 with recovered testosterone 5 years after completion of therapy. Secondary endpoints included time to progression (TTP), time to reinitiate androgen deprivation therapy (ADT), the proportion with castration-resistant prostate cancer (CRPC), and overall survival (OS). RESULTS: Median follow-up was 8.6 years (range 1.3-11.1 years). At 5 year follow-up, 7 patients (11%) had PSA <0.1 (5 undetectable); 8 (13%) had PSA >0.1 but without reinitiation of ADT (median PSA 0.37). Of the 15 (24%) men without reinitiation of ADT, and 14 have recovered testosterone to normal range. Median TTP for the complete cohort was 35.0 months (95% confidence interval [CI] 31.7-39.2). Baseline PSA <3.0 ng/dL, no prior ADT, and prostatectomy (vs radiation) were associated with longer TTP (P = .0001, P = .0055, and P = .0398, respectively). At the time of analysis, 42 men (68%) had restarted ADT, 23 men had CRPC (37%), and 11 (18%) had chemotherapy. Median time to reinitiation of ADT was 32.6 months (range 0-107.6 months). Median OS has not been reached; there were 15 deaths. CONCLUSION: Chemotherapy plus ADT for BR resulted in durable (>5 years) complete responses (<0.1 ng/mL) in 7 men (11%). Twenty-four percent of men have not re-initiated ADT 5 years from completion of protocol therapy.

Copyright © 2013 Elsevier Inc. All rights reserved.

relatesTo
type: comment-in
classifier: Comment
citation:
J Urol. 2013 Sep;190(3):880. doi: 10.1016/j.juro.2013.05.105

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/23931194/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23931194
publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/1527-9995, ISOAbbreviation/Urology, ISSN Linking/0090-4295, Medline Title Abbreviation/Urology, NLM Unique ID/0366151
title: Urology
publisherLocation: United States
citedMedium: Internet
volume: 81
issue: 3
articleDate: 2013-03
publicationDateText: 2013-Mar
language: English
pageString: 611-6
webLocation
classifier: Abstract
url: https://pubmed.ncbi.nlm.nih.gov/23452809/
webLocation
classifier: DOI Based
url: https://doi.org/10.1016/j.urology.2012.12.025
classification
type: Publishing Model
classifier: Print
classification
type: Chemical
classifier: Androgen Antagonists, Anilides, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Nitriles, Taxoids, Tosyl Compounds, Goserelin, Docetaxel, Estramustine, bicalutamide
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Nakabayashi M
forenameInitials: M
affiliation: Division of Medical Oncology, Department of Medicine, Lank Center for Genitourinary Oncology, Boston, MA 02215, USA.
entry
contributor: Xie W
forenameInitials: W
entry
contributor: Buckle G
forenameInitials: G
entry
contributor: Bubley G
forenameInitials: G
entry
contributor: Ernstoff MS
forenameInitials: MS
entry
contributor: Walsh W
forenameInitials: W
entry
contributor: Morganstern DE
forenameInitials: DE
entry
contributor: Kantoff PW
forenameInitials: PW
entry
contributor: Taplin ME
forenameInitials: ME

Generated Narrative: Practitioner #contributor0

name: Mari Nakabayashi

Generated Narrative: Practitioner #contributor1

name: Wanling Xie

Generated Narrative: Practitioner #contributor2

name: Geoffrey Buckle

Generated Narrative: Practitioner #contributor3

name: Glenn Bubley

Generated Narrative: Practitioner #contributor4

name: Marc S Ernstoff

Generated Narrative: Practitioner #contributor5

name: William Walsh

Generated Narrative: Practitioner #contributor6

name: Daniel E Morganstern

Generated Narrative: Practitioner #contributor7

name: Philip W Kantoff

Generated Narrative: Practitioner #contributor8

name: Mary-Ellen Taplin

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Anilides
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Antineoplastic Agents
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Antineoplastic Agents, Hormonal
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Antineoplastic Combined Chemotherapy Protocols
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Docetaxel
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Drug Therapy, Combination
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Estramustine
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Follow-Up Studies
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Goserelin
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Neoplasm Recurrence, Local
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Nitriles
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Retrospective Studies
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Taxoids
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Time Factors
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Tosyl Compounds
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Treatment Outcome
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic